에 대한 최신 뉴스 JD.com (OTC:JDCMF) 주식

JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.

Asia

Equities

News

Markets

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

BIDU

JDCMF

MPNGY

TCEHY

목요일(6일) 오전 홍콩 증시는 항셍지수가 2.5% 상승한 24,183.07포인트를 기록하며 2022년 1월 이후 최고치를 기록했다. 연간 상승률은 23.37%로 확대되었다.무슨 일 있었나: 홍콩증권거래소에서 중국 기술 대기업들이 랠리를 주도했다.

알리바바, 중국 정부의 AI 지원 약속에 주가 7% 상승...항셍지수 2년래 최고점

Palantir, Carvana, Enovix, Grab, Tesla: Why These 5 Stocks Are On Investors' Radars Today

BAIDF

XIACY

금요일(21일) 중국 기술주가 급등했다. 알리바바(OTC:BABAF)(NYSE:BABA)가 12% 이상 급등하는 등 투자자들이 긍정적인 실적 가이던스와 중국의 통화 정책 완화에 대한 기대감에 반응했다.

알리바바, 홍콩 거래에서 12% 이상 급등: 중국 지원책 기대 속 텐센트·샤오미 등 중국 기술주 동반 랠리

JD.com Inc

Mizuho analyst Maheep Mandloi maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Outperform and lowers the price target from $61 to $53.

Price Target

Analyst Ratings

ENPH

Mizuho Maintains Outperform on Enphase Energy, Lowers Price Target to $53

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>BMO Capital analyst Katja Jancic upgraded the rating for Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) from Market Perform to Outperform and raised the price target from $140 to $145. Nucor shares closed at $109.36 on Friday. <a href="https://www.benzinga.com/quote/NUE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Jordan Alliger upgraded Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) from Neutral to Buy and raised the price target from $387 to $410. Saia shares closed at $264.41 on Friday. <a href="https://www.benzinga.com/quote/SAIA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>RBC Capital analyst Nik Modi upgraded Church &amp; Dwight Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) from Sector Perform to Outperform and boosted the price target from $100 to $114. Church &amp; Dwight shares closed at $98.31 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Ronald Epstein upgraded The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) from Neutral to Buy and raised the price target from $185 to $260. Boeing shares closed at $207.32 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Stephanie Moore upgraded the rating for Rollins, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) from Hold to Buy and raised the price target from $55 to $65. Rollins shares closed at $57.25 on Friday. <a href="https://www.benzinga.com/quote/rol/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NUE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-1024x575.png" alt="" class="wp-image-935167" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02085339/image-8.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Trading Ideas

SAIA

This Nucor Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Needham analyst Ami Fadia downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Buy to Hold and maintains the price target from $130 to $130.

Downgrades

BPMC

Needham Downgrades Blueprint Medicines to Hold, Maintains Price Target to $130

Six in ten working-age Americans fear Social Security will vanish before they retire, a new DepositAccounts survey finds, underscoring a widening confidence gap as the program's main trust fund edges toward depletion in 2033.
What Happened: The poll of 1,047 non-retirees shows 59% doubt the program will exist by the time they hang up their paychecks. The anxiety is sharpest for Generation X, where 70% share the concern. That dread persists even though Social Security still supplies more than half of all income for 40% of today's retirees, according to the Social Security Administration.
As per this year's trustees report, the Old-Age and Survivors Insurance fund can pay full benefits for just eight more years. Once its reserves run dry, incoming payroll taxes would cover only 79% of promised checks. "It's not that far away. We're creeping up on it," certified-financial-planner Jaime Eckels <a href="https://www.cnbc.com/2025/05/30/majority-of-working-americans-fear-social-security-will-dry-up.html">told</a> CNBC, warning that the countdown has moved from abstract to immediate for many savers.
Polling elsewhere points in the same direction, or worse. Gallup in 2024 reports 80% of Americans now worry about Social Security's future, the highest share in two decades. Transamerica's 2024 middle-class survey shows 39% of households fear benefits "will be reduced or cease to exist."
See also: <a href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals">Moderna&#8217;s New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals</a>
Still, not every gauge is as bleak. The 2025 Retirement Confidence Survey from the Employee Benefit Research Institute found about half of workers remain at least "somewhat confident" the government will pay benefits of equal value to today's. Even so, 60% worry about cuts.
Why It Matters: Analysts stress that insolvency does not equal disappearance. "The truth is that it's highly, highly unlikely Social Security ‘won't be available,'" DepositAccounts quoted LendingTree's Matt Schulz as saying, urging savers to bolster private nest eggs rather than panic. That mirrors comments by BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) chief Larry Fink, who <a href="https://www.benzinga.com/personal-finance/25/03/44427073/larry-fink-says-the-u-s-needs-a-social-security-plan-where-every-american-can-grow-with-our-economy">recently told</a> an audience that the U.S. must modernize, not abandon, the program — citing the same <a href="https://www.benzinga.com/personal-finance/24/09/40817544/report-warns-of-16-500-annual-social-security-benefit-cut-for-dual-income-couples-by-2033">2033 deadline</a>.
Yet fear itself is already reshaping behavior. A growing number of claimants are <a href="https://www.benzinga.com/25/05/45265236/80000-more-americans-filed-for-social-security-in-march-compared-with-last-year-whats-driving-this-surge">taking benefits at 62</a> to grab what they can before any reforms bite, despite the <a href="https://www.benzinga.com/personal-finance/25/05/45354988/suze-orman-taking-your-social-security-payments-at-62-is-wrong-heres-why">permanent haircut</a> early filing brings.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/personal-finance/management/25/06/45719596/bill-gates-22-year-old-daughter-says-its-terrifying-for-the-boys-she-brings-home-to-meet-her-socially-awkward-dad-in-his-63-million-mansion">Bill Gates&#8217; 22-Year-Old Daughter Says It&#8217;s &#8216;Terrifying&#8217; For The Boys She Brings Home to Meet Her &#8216;Socially Awkward&#8217; Dad in His $63 Million Mansion</a>

Personal Finance

General

6 In 10 Americans Fear Social Security Will Vanish Before They Retire, As 2033 Insolvency Clock Ticks Louder

Mizuho analyst Maheep Mandloi maintains Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) with a Outperform and lowers the price target from $17 to $15.

CSIQ

Mizuho Maintains Outperform on Canadian Solar, Lowers Price Target to $15

MULN

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

APDN

WIIM

MRNA

Moderna shares are trading higher after the company announced its new COVID-19 vaccine secured FDA clearance for seniors and at-risk individuals.

HC Wainwright &amp; Co. analyst Arthur He maintains Vera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with a Buy and raises the price target from $75 to $85.

VERA

HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $85

Mizuho analyst John Roberts maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Outperform and lowers the price target from $100 to $82.

Mizuho Maintains Outperform on Westlake, Lowers Price Target to $82

Wells Fargo initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Equal-Weight rating and announces Price Target of $37.

Initiation

Wells Fargo Initiates Coverage On Aspen Insurance Hldgs with Equal-Weight Rating, Announces Price Target of $37

CRWV

CoreWeave shares are trading higher after announcing Applied Digital signed a 250MW AI data center lease with the company.

Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $280 to $295.

VEEV

Mizuho Maintains Outperform on Veeva Systems, Raises Price Target to $295

Fly-E Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) ("Fly-E" or the "Company"), an electric vehicle company engaged in designing, installing, selling, and renting smart electric motorcycles, electric bikes, and electric scooters, today announced the pricing of its public offering of 28,595,553 shares of common stock (the "Common Stock") and 57,191,106 warrants (the "Warrants") to purchase Common Stock (including shares of Common Stock underlying warrants) at a public offering price of $0.2428. Each share of Common Stock is being sold together with two Warrants, with each Warrant to purchase one share of Common Stock. Each Warrant is exercisable immediately with an exercise price equal to 120% of the offering price ($0.2913 per share), and expires on the fifth anniversary of the issuance date, subject to certain adjustments.
The offering is expected to close on or about June 3, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds to the Company, before deducting placement agent's fees and other offering expenses, are expected to be approximately $6.94 million. The Company intends to use the net proceeds of this offering for purchase of inventory and production costs of its vehicles and working capital.
American Trust Investment Services, Inc. is acting as exclusive placement agent in connection with the offering.

Offerings

FLYE

Fly-E Group Prices $6.94M Public Offering Of 28.6M Shares And 57.2M 5-Year Warrants At $0.2428 Per Unit

UBS analyst Damian Karas upgrades SPX Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPXC#NYSE">SPXC</a>) from Neutral to Buy and raises the price target from $160 to $182.

SPXC

UBS Upgrades SPX Technologies to Buy, Raises Price Target to $182

PDSB

PDS Biotechnology shares are trading lower. The company provided updates and survival data for its VERSATILE-002 trial.

Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten public offering of pre-funded warrants to purchase 66,676,000 shares of common stock (the "pre-funded warrants"), accompanied by Series A warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the "Series A warrants"), Series B warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the "Series B warrants") and Series C warrants to purchase 66,676,000 shares of common stock (or, in certain circumstances, pre-funded warrants) (the "Series C warrants"). The combined public offering price of one pre-funded warrant, one Series A warrant, one Series B warrant and one Series C warrant, which are being sold together but are immediately separable, is $0.7499, which is equal to the combined offering price of the pre-funded warrants, Series A warrants, Series B warrants and Series C warrants, less the $0.0001 per share exercise price of the pre-funded warrants. The offering is expected to close on or about June 5, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Xilio.
The pre-funded warrants will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. The Series A warrants will be exercisable the earlier of (i) December 1, 2025 and (ii) the trading day immediately following a period of five consecutive trading days on which the closing sale price of our common stock is a minimum of $1.50 per share, with an exercise price of $0.75 per share of common stock, and will expire five years from the date of issuance. In addition, each Series A warrant will immediately expire in proportion to the extent that the corresponding pre-funded warrant offered hereby is exercised on or prior to December 1, 2025; provided that this term will no longer apply to the Series A warrants beginning on the first the trading day immediately following a period of five consecutive trading days on which the closing sale price of our common stock is a minimum of $1.50 per share. The Series B Warrants will be exercisable on or after November 1, 2025, with an exercise price of $0.75 per share of common stock, and will expire on December 2, 2025, subject to certain extensions. The Series C Warrants will be exercisable on or after June 1, 2026, with an exercise price of $0.75 per share of common stock, and will expire on the earlier of (i) December 2, 2026 and (ii) the expiration time of the Series B warrant held by a holder in proportion to the extent that the corresponding Series B warrant expires without being exercised, subject to certain extensions.
The initial gross proceeds from the offering are expected to be approximately $50.0 million before deducting underwriting discounts and commissions and offering expenses. The pre-funded warrants and Series A warrants may be exercised for cash or on a net exercise or "cashless" basis, and the Series B warrants and Series C warrants may be exercised for cash or on a net exercise or "cashless" basis provided there is no effective registration statement or prospectus available which covers the Series B warrants and Series C warrants and shares of common stock issuable upon exercise of the Series B warrants and Series C warrants. If all of the Series B warrants and Series C warrants are exercised in cash at their exercise price, the Company may receive additional gross proceeds from the offering of up to approximately $100.0 million before deducting underwriting discounts and commissions and offering expenses.

Xilio Therapeutics Prices $50M Public Offering Of Pre-Funded Warrants And Series A, B, C Warrants To Purchase 66.7M Shares Each At $0.7499 Per Unit; Co May Receive Additional Gross Proceeds From The Offering Of Up To ~$100M Before Deducting Underwriting Discounts And Commissions And Offering Expenses

U.S. Gold Corp. ("U.S. Gold," the "Company," "we," "our" or "us") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAU#NASDAQ">USAU</a>) is pleased to announce&nbsp;that we have met the criteria for inclusion in the broad-market Russell 3000 Index (the "Russell 3000") and the small-cap Russell 2000 Index (the "Russell 2000") at the conclusion of the Russell indexes annual reconstitution, effective after the U.S. market opens on&nbsp;June 30, 2025, according to a preliminary list of additions posted&nbsp;Friday, May 23, 2025.

USAU

U.S. Gold Corp Joins Russell 3000 And Russell 2000 Indexes Following Annual Reconstitution

Scotiabank analyst Maher Yaghi upgrades BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) from Sector Perform to Sector Outperform and announces C$39 price target.

TSX:BCE

Scotiabank Upgrades BCE to Sector Outperform, Announces C$39 Price Target

Morgan Stanley analyst Devin McDermott maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Equal-Weight and raises the price target from $132 to $135.

Morgan Stanley Maintains Equal-Weight on EOG Resources, Raises Price Target to $135

JD.com

목요일(6일) 오전 홍콩 증시는 항셍지수가 2.5% 상승한 24,183.07포인트를 기록하며 2022년 1월 이후 최고치를 기록했다. 연간 상승률은 23.37%로 확대되었다.
무슨 일 있었나: 홍콩증권거래소에서 중국 기술 대기업들이 랠리를 주도했다. 알리바바 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#OTC">BABAF</a>) 주가가 7.24% 상승한 139.30 HKD($17.93), 텐센트(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>) 주가가 5.84% 상승한 534.00 HKD($68.72)에 거래되었다.
다른 주요 기술 기업들도 상당한 상승세를 보였는데 바이두(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>)는 3.83% 상승하여 90.80 HKD($11.68), JD닷컴(OTC:<a class="ticker" href="https://www.benzinga.com/stock/JDCMF#OTC">JDCMF</a>)은 4.06% 상승하여 171.20 HKD($22.03), 메이투안(OTC:<a class="ticker" href="https://www.benzinga.com/stock/MPNGY#OTC">MPNGY</a>)은 4.08% 상승하여 179.50 HKD($23.10)에 거래되었다.
로이터 통신은 수요일 중국 전국인민대표대회에서 리창 총리가 재정 부양책을 확대하겠다고 발표한 이후 시장 랠리가 이어졌다고 보도했다. 리 총리는 부진한 소비를 "적극적으로 부양"하고 미국 무역 긴장 고조로 인한 충격을 완화하는 동시에 2025년 중국의 5% 성장 목표를 유지하겠다고 약속했다.
리 총리는 "점점 더 복잡하고 어려워지는 외부 환경이 무역, 과학, 기술 등의 분야에서 중국에 더 큰 영향을 미칠 수 있다"고 경고하며 "한 세기 동안 보지 못한 변화"를 언급했다.
왜 중요한가: 중국은 올해 1.3조 위안(1,790 억 달러)의 초장기 특별 국채를 발행할 계획이며 2024년 1조 위안보다 증가한 수치다. 또한 지방 정부가 4.4조 위안의 특별 부채를 발행할 수 있도록 허용할 것이며, 예산 적자는 GDP의 약 4%까지 확대될 것으로 예상된다.
투자자들은 특히 리 총리가 전기차, 스마트폰, 로봇 전반에 걸쳐 인공지능(AI) 애플리케이션을 육성하겠다고 약속하면서 중국의 AI 야망에 열광하고 있는 것으로 보인다. 최근 AI 플랫폼 딥시크의 등장으로 시장 분위기는 더욱 고조되었으며, 알리바바도 오늘 새로운 QwQ-32B 추론 모델을 발표했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Today, we release QwQ-32B, our new reasoning model with only 32 billion parameters that rivals cutting-edge reasoning model, e.g., DeepSeek-R1.
Blog: <a href="https://t.co/zCgACNdodj">https://t.co/zCgACNdodj</a> HF: <a href="https://t.co/pfjZygOiyQ">https://t.co/pfjZygOiyQ</a> ModelScope: <a href="https://t.co/hcfOD8wSLa">https://t.co/hcfOD8wSLa</a> Demo: <a href="https://t.co/DxWPzAg6g8">https://t.co/DxWPzAg6g8</a> Qwen Chat:… <a href="https://t.co/kfvbNgNucW">pic.twitter.com/kfvbNgNucW</a>
&mdash; Qwen (@Alibaba_Qwen) <a href="https://twitter.com/Alibaba_Qwen/status/1897361654763151544?ref_src=twsrc%5Etfw">March 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

금요일(21일) 중국 기술주가 급등했다. 알리바바(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BABAF#OTC">BABAF</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)가 12% 이상 급등하는 등 투자자들이 긍정적인 실적 가이던스와 중국의 통화 정책 완화에 대한 기대감에 반응했다.
무슨 일 있었나: 알리바바의 주가는 에디 우 CEO가 다음 회계연도에 국제 상거래 부문이 수익성을 달성할 것으로 기대한다고 발표한 후 현지시간 11:35 AM 기준 135.50홍콩달러까지 상승했다.
텐센트 홀딩스(OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCEHY#OTC">TCEHY</a>)는 4.56% 상승한 509.99홍콩달러, 샤오미(OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>)는 5.09% 상승한 51.65홍콩달러, 바이두(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAIDF#OTC">BAIDF</a>)는 2.92% 상승한 88.00달러, JD닷컴(OTC:<a class="ticker" href="https://www.benzinga.com/stock/JDCMF#OTC">JDCMF</a>)은 3.19% 상승한 158.60홍콩달러에 거래되고 있다.
이러한 급등은 경제학자들이 중국 중앙은행이 3월 연례 의회 회의 이후 주요 정책 금리를 인하할 수 있다고 예측함에 따라 발생했다. 중국 인민은행(PBOC)은 목요일 대출 기준금리를 유지하면서 1년 만기 금리는 3.1%, 5년 만기 금리는 3.6%로 유지했다.
홍콩중문대 경영대학원의 부교수인 브루스 팡은 <a href="https://www.cnbc.com/2025/02/20/china-lpr-decision-february.html">CNBC와 인터뷰에서</a> 다음 달 지급준비율이 50bp 인하되고 7일 역레포 금리는 올해 40~50bp 하락할 가능성이 있다고 전망했다.
왜 중요한가: 기술 부문의 모멘텀은 저명한 기술 리더들이 참여한 고위급 비즈니스 심포지엄에서 시진핑 중국 주석이 보여 준 민간 기업에 대한 지지 입장 등 <a href="https://www.benzinga.com/markets/asia/25/02/43772586/xi-jinpings-supportive-business-stance-sparks-rally-for-second-day-alibaba-xiaomi-surge-over-4-on-hong-kong-exchange">최근 낙관론을 기반으로 한다</a>. 특히 알리바바의 창업자 마윈이 중국의 2020년 규제 단속 이후 처음으로 최고 지도부와 함께 공개 석상에 모습을 드러냈다.
그러나 최근 도널드 트럼프 행정부가 부과한 관세와 연준의 신중한 금리인하 접근이 인민은행의 통화정책 결정에 영향을 미칠 수 있기 때문에 투자자들은 미중 긴장 관계를 주시하고 있다.
이미지 출처: Shutterstock
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토하고 게시했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

JD.com

뉴스

에 대한 최신 뉴스 JD.com (OTC:JDCMF) 주식

목요일, 3월 06, 2025

금요일, 2월 21, 2025

뉴스

파트너 / 기고자

벤징가 글로벌